Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer

Annals of Oncology

Volumn 14, Issue 1, 2003, Pages 85-90

  Gazzaniga, P ^a   Gradilone, A ^a   Giuliani, L ^a   Gandini, O ^a   Silvestri, I ^a   Nofroni, I ^a   Saccani, G ^b   Frati, L ^a   Aglianò, Anna Maria ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

BCL 2 BAX; BCL X; Bladder cancer; LIVIN; Relapse; SURVIVIN

Indexed keywords

APOPTOSIS INHIBITOR; BCG VACCINE; ISOPROTEIN; MITOMYCIN C; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN BCL XL; PROTEIN LIVIN; PROTEIN SURVIVIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER RECURRENCE; CANCER RISK; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN TISSUE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOLID TUMOR; STATISTICAL SIGNIFICANCE; SUPERFICIAL CANCER; TRANSURETHRAL RESECTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; CARCINOMA, TRANSITIONAL CELL; CARRIER PROTEINS; DNA PRIMERS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 0037249506     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg002     Document Type: Article

References (19)

1. Ozen H, Hall MC. Bladder cancer. Curr Opin Oncol 2000; 12: 255-259.
2. Stein JP, Grossfeld GD, Ginsberg DA et al. Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol 1998; 160: 645-659.
3. Lee E, Park I, Lee C. Prognostic markers of intravesical bacillus Calmette-Guerìn therapy for multiple, high grade, stage T1 bladder cancer. Int J Urol 1997; 4: 552-556.
4. Gazzaniga P, Gallucci M, Gradilone A et al. Detection of BCL-2 RNA in low grade tumours of the urinary bladder. Eur J Cancer 1995; 131A: 2119-2120.
5. Gazzaniga P, Gradilone A, Vercillo R et al. BCL-2/BAX mRNA expression ratio as prognostic factor in low grade urinary bladder cancer. Int J Cancer 1996; 69: 100-104.
6. Ashhab Y, Alian A, Polliack A et al. Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern. FEBS Lett 2001; 495: 56-60.
7. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, SURVIVIN, expressed in cancer and lymphoma. Nature Med 1997; 3: 917-921.
8. Lu CD, Altieri DC, Tanigawa N. Expression of a novel antiapoptosis gene, SURVIVIN, correlates with tumor cell apoptosis and p53 accumulation in gastric carcinoma. Cancer Res 1998; 58; 1808-1812.
9. Grossman D, McNiff JM, Li F, Altieri DC. Expression and targeting of the apoptosis inhibitor SURVIVIN in human melanoma. J Invest Dermatol 1999; 113: 1076-1081.
10. Kawasaki H, Altieri DC, Lu CD et al. Inhibition of apoptosis by SURVIVIN predicts shorter survival rates in colorectal cancer. Cancer Res 1998; 58: 5071-5074.
11. Swana HS, Grossman D, Anthony JN et al. Tumor content of the anti-apoptotic molecule SURVIVIN and recurrence of bladder cancer. N Engl J Med 1999; 341: 452-453.
12. Smith SD, Wheeler MA, Plescia J et al. Urine detection of SURVIVIN and diagnosis of bladder cancer. JAMA 2001; 285: 324-328.
13. Gazzaniga P, Gradilone A, Silvestri I et al. Variable levels of BCL-2, BCL-X and BAX mRNA in bladder cancer progression. Oncol Rep 1998; 5: 901-904.
14. Pompeo E, Sergiacomi G, Nofroni I et al. Morphologic grading of emphysema is useful in the selection of candidates for unilateral or bilateral reduction pneumoplasty. Eur J Card Thor Surg 2000; 17: 680-686.
15. Miyake H, Hara I, Yamanaka K et al. Synergistic enhancement of resistance to cisplatin in human bladder cancer cells by overexpression of mutant type p53 and BCL-2. J Urol 1999; 162: 2167-2181.
16. Waf1/Cip1 acts in synergy with BCL-2 to confer multidrug resistance in a camptothecin-selected human lung cancer cell line. Int J Cancer 1999; 83: 790-797.
17. Yang OF, Sakurai T, Yashimura G et al. Expression of BCL-2 but not BAX or p53 correlates with in vitro resistance to a series of anticancer drugs in breast carcinoma. Breast Cancer Res Treat 2000; 61: 211-216.
18. Buolamwini JK. Novel anticancer drug discovery. Curr Opin Chem Biol 1999; 3: 500-509.
19. Pawinski A, Sylvester R, Kurth KH et al. A combined analysis of European Organization for Research and Treatment of Cancer and Medical Research Council randomized clinical trials for the prophylactic treatment of stage Ta T1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J Urol 1996; 156: 1934-1940.